{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:41:03Z","timestamp":1792453263418,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02945-5","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:02:24Z","timestamp":1792450944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world renoprotective effects of polyethylene glycol-loxenatide in type 2 diabetes: a multicenter, ambispective cohort study"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-0576","authenticated-orcid":false,"given":"Junjun","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-0068","authenticated-orcid":false,"given":"Kaijian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"2945_CR1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"2945_CR2","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Diabetes and chronic kidney disease in Chinese adults: a population-based cohort study. BMJ Open Diabetes Res. Care. 12 https:\/\/doi.org\/10.1136\/bmjdrc-2023-003721 (2024).","DOI":"10.1136\/bmjdrc-2023-003721"},{"key":"2945_CR3","doi-asserted-by":"publisher","first-page":"sfaf265","DOI":"10.1093\/ckj\/sfaf265","volume":"18","author":"Y He","year":"2025","unstructured":"He, Y. et al. Three decades of CKD due to diabetes mellitus type 2 in China, with projections of disease burden from 2022 to 2036: a systematic analysis for the Global Burden of Disease Study 2021. Clin. Kidney J. 18, sfaf265 (2025).","journal-title":"Clin. Kidney J."},{"key":"2945_CR4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer, I. H. et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 102, 974\u2013989 (2022).","journal-title":"Kidney Int."},{"key":"2945_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12933-021-01229-2","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano, D., Maiorino, M. I., Bellastella, G. & Esposito, K. The residual cardiorenal risk in type 2 diabetes. Cardiovasc. Diabetol. 20, 36 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"2945_CR6","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos, E. D., Bakris, G. L., Rodbard, H. W. & Tuttle, K. R. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Am. J. Prev. Cardiol. 14, 100502 (2023).","journal-title":"Am. J. Prev. Cardiol."},{"key":"2945_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2945_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"2945_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2945_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano, D. et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc. Diabetol. 20, 189 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"2945_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/jcph.386","volume":"55","author":"GR Yang","year":"2015","unstructured":"Yang, G. R. et al. Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes. J. Clin. Pharm. 55, 152\u2013158 (2015).","journal-title":"J. Clin. Pharm."},{"key":"2945_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70094","volume":"6","author":"J Li","year":"2025","unstructured":"Li, J. et al. Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial). MedComm 6, e70094 (2025).","journal-title":"MedComm"},{"key":"2945_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.781856","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Protective effects and mechanisms of polyethylene glycol loxenatide against hyperglycemia and liver injury in db\/db diabetic mice. Front. Pharm. 12, 781856 (2021).","journal-title":"Front. Pharm."},{"key":"2945_CR14","doi-asserted-by":"publisher","first-page":"AIoa2400181","DOI":"10.1056\/AIoa2400181","volume":"1","author":"O Unlu","year":"2024","unstructured":"Unlu, O. et al. Retrieval-augmented generation\u2013enabled GPT-4 for clinical trial screening. NEJM AI 1, AIoa2400181 (2024).","journal-title":"NEJM AI"},{"key":"2945_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An Introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46, 399\u2013424 (2011).","journal-title":"Multivar. Behav. Res."},{"key":"2945_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.7326\/M22-1510","volume":"176","author":"JB Segal","year":"2023","unstructured":"Segal, J. B. et al. Assessing heterogeneity of treatment effect in real-world data. Ann. Intern. Med. 176, 536\u2013544 (2023).","journal-title":"Ann. Intern. Med."},{"key":"2945_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jama.2018.10136","volume":"320","author":"J Corrigan-Curay","year":"2018","unstructured":"Corrigan-Curay, J., Sacks, L. & Woodcock, J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA 320, 867\u2013868 (2018).","journal-title":"JAMA"},{"key":"2945_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa, S. Immortal time bias in pharmaco-epidemiology. Am. J. Epidemiol. 167, 492\u2013499 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"2945_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1357","volume":"16","author":"S Suissa","year":"2007","unstructured":"Suissa, S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol. Drug Saf. 16, 241\u2013249 (2007).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"2945_CR20","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/aje\/kwab041","volume":"190","author":"T St\u00fcrmer","year":"2021","unstructured":"St\u00fcrmer, T. et al. Propensity score weighting and trimming strategies for reducing variance and bias of treatment effect estimates: a simulation study. Am. J. Epidemiol. 190, 1659\u20131670 (2021).","journal-title":"Am. J. Epidemiol."},{"key":"2945_CR21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1186\/s12872-024-04427-4","volume":"24","author":"C Shi","year":"2024","unstructured":"Shi, C. et al. Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78\/PERK\/eIF2\u03b1 pathway, and improves cardiac injury by suppressing TLR4\/NF-\u03baB inflammatory pathway. BMC Cardiovasc. Disord. 24, 704 (2024).","journal-title":"BMC Cardiovasc. Disord."},{"key":"2945_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","volume":"105","author":"KC Sourris","year":"2024","unstructured":"Sourris, K. C. et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int. 105, 132\u2013149 (2024).","journal-title":"Kidney Int."},{"key":"2945_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bbrc.2023.04.012","volume":"664","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning. Biochem. Biophys. Res. Commun. 664, 142\u2013151 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2945_CR24","doi-asserted-by":"publisher","first-page":"1747053","DOI":"10.3389\/fphys.2026.1747053","volume":"17","author":"S Al-Masri","year":"2026","unstructured":"Al-Masri, S., Coelho, J. N. & Thomas, L. Molecular pathways and emerging therapeutic targets in the pathogenesis of diabetic kidney disease. Front Physiol. 17, 1747053 (2026).","journal-title":"Front Physiol."},{"key":"2945_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00592-023-02184-y","volume":"61","author":"X Li","year":"2024","unstructured":"Li, X. et al. GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis. Acta Diabetol. 61, 225\u2013234 (2024).","journal-title":"Acta Diabetol."},{"key":"2945_CR26","doi-asserted-by":"publisher","first-page":"F442","DOI":"10.1152\/ajprenal.00194.2020","volume":"320","author":"EA Jaimes","year":"2021","unstructured":"Jaimes, E. A. et al. Nicotine, smoking, podocytes, and diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 320, F442\u2013f453 (2021).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"2945_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/aje\/kwn135","volume":"168","author":"S Suissa","year":"2008","unstructured":"Suissa, S. Immeasurable time bias in observational studies of drug effects on mortality. Am. J. Epidemiol. 168, 329\u2013335 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"2945_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2024.28047","volume":"333","author":"O Unlu","year":"2025","unstructured":"Unlu, O. et al. Manual vs AI-assisted prescreening for trial eligibility using large language models\u2014a randomized clinical trial. JAMA 333, 1084\u20131087 (2025).","journal-title":"JAMA"},{"key":"2945_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern Med. 167, 268\u2013274 (2017).","journal-title":"Ann. Intern Med."},{"key":"2945_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","volume":"4","author":"U Dafni","year":"2011","unstructured":"Dafni, U. Landmark analysis at the 25-year landmark point. Circ. Cardiovasc Qual. Outcomes 4, 363\u2013371 (2011).","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"2945_CR31","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194 (2013).","DOI":"10.1001\/jama.2013.281053"},{"key":"2945_CR32","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","volume":"26","author":"S Thompson","year":"2015","unstructured":"Thompson, S. et al. Cause of death in patients with reduced kidney function. J. Am. Soc. Nephrol. 26, 2504\u20132511 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2945_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 10, 150\u2013161 (2011).","journal-title":"Pharm. Stat."},{"key":"2945_CR34","unstructured":"R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2024)."},{"key":"2945_CR35","unstructured":"Therneau, T. M. A Package for Survival Analysis in R (R package version 3.8-7, 2026). Available from: https:\/\/CRAN.R-project.org\/package=survival"},{"key":"2945_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"D Ho","year":"2011","unstructured":"Ho, D., Imai, K., King, G. & Stuart, E. A. MatchIt: nonparametric preprocessing for parametric causal inference. J. Stat. Softw. 42, 1\u201328 (2011).","journal-title":"J. Stat. Softw."},{"key":"2945_CR37","unstructured":"Kassambara, A. & Kassambara, M. A. survminer: Drawing Survival Curves using 'ggplot2' (R package version 0.5.2.999, 2026). Available from: https:\/\/CRAN.R-project.org\/package=survminer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02945-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02945-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02945-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:02:25Z","timestamp":1792450945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02945-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2945"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02945-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. While the primary baseline study (FLYING 1) received support from Jiangsu Hansoh Pharmaceutical Group Co., Ltd., the sponsor played no role in the design, execution, analysis, or funding of this secondary extended study (FLYING 2).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"456"}}